表紙
市場調查報告書

焦點市場分析:化膿性汗腺炎

Market Spotlight: Hidradenitis Suppurativa

出版商 Datamonitor Healthcare 商品編碼 633141
出版日期 內容資訊 英文 34 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
焦點市場分析:化膿性汗腺炎 Market Spotlight: Hidradenitis Suppurativa
出版日期: 2019年11月07日內容資訊: 英文 34 Pages
簡介

本報告提供全球化膿性汗腺炎市場相關調查,彙整化膿性汗腺炎概要和治療,已上市及近幾年的開發平台藥物,收益的機會,臨床實驗趨勢等相關資訊。

概要

疾病概要

治療

疾病概要

  • 化膿性汗腺炎亞型

已上市藥物

  • 美國的開發平台藥物

主要的法律規章活動

  • CI的Cyltezo成為今年第15次的EU生物相似藥·of·The year(ear)
  • Amgen的Amjevita被批准為AbbVie的Humira的第一個生物仿製藥
  • 三星Bioepis在歐洲成立生物相似藥的企業
  • 歐盟CHMP確定Imraldi,三星Bioepis生物仿製藥AbbVie的Humira
  • Amgen的生物相似藥Adalimumab首次投入歐洲,但沒有啟動

專利

商機

臨床實驗趨勢

參考文獻

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0189155

This Market Spotlight report covers the Hidradenitis Suppurativa market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

All of the approved drugs for hidradenitis suppurativa (HS) target tumor necrosis factor-alpha. These therapies are administered via the subcutaneous route, while Humira is also available in an intravenous formulation.

The majority of industry-sponsored drugs in active clinical development for HS are in Phase II. Therapies in development for HS target tumor necrosis factor-alpha, interleukin-17, interleukin-1, interleukin-23, JAK/STAT, and the C5a receptor. These therapies are administered via the oral, intravenous, and subcutaneous routes.

The only high-impact upcoming event in the HS space is topline Phase II trial results for avacopan. The overall likelihood of approval of a Phase I dermatology-general asset is 25.4%, and the average probability a drug advances from Phase III is 75.8%. Drugs, on average, take 8.1 years from Phase I to approval, compared to 8.0 years in the overall dermatology space.

There have been only seven licensing and asset acquisition deals involving HS drugs during 2014-19. The values have not been disclosed for any of these deals.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for HS have been in the early and midphases of development, with 83% of trials in Phase I-II, and only 17% in Phase III-IV.

The US has the lead in terms of the number of HS clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.

Abbott has the highest number of completed clinical trials for HS, with two trials.

AbbVie is the only sponsor to have initiated a Phase III and Phase IV trial in HS.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • IFX-1 for HS (July 18, 2019)
  • IFX-1 for HS (June 5, 2019)
  • SensoReady Injector Pen for HS (April 9, 2019)
  • Bermekimab for HS (January 23, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Overview of pipeline drugs for HS in the US
  • Figure 2: Pipeline drugs for HS, by company
  • Figure 3: Pipeline drugs for HS, by drug type
  • Figure 4: Pipeline drugs for HS, by classification
  • Figure 5: IFX-1 for HS (June 5, 2019): Phase IIb - SHINE
  • Figure 6: Bermekimab for HS (January 23, 2019): Phase II - Open Label
  • Figure 7: Key upcoming events in HS
  • Figure 8: Probability of success in the HS pipeline
  • Figure 9: Licensing and asset acquisition deals in HS, 2014-19
  • Figure 10: Clinical trials in HS
  • Figure 11: Top 10 drugs for clinical trials in HS
  • Figure 12: Top 10 companies for clinical trials in HS
  • Figure 13: Trial locations in HS
  • Figure 14: HS trials status
  • Figure 15: HS trials sponsors, by phase

LIST OF TABLES

  • Table 1: Marketed drugs for HS
  • Table 2: Pipeline drugs for HS in the US
  • Table 3: IFX-1 for HS (July 18, 2019)
  • Table 4: IFX-1 for HS (June 5, 2019)
  • Table 5: SensoReady Injector Pen for HS (April 9, 2019)
  • Table 6: Bermekimab for HS (January 23, 2019)
  • Table 7: Parent patents in HS
  • Table 8: Historical global sales, by drug ($m), 2014-18
  • Table 9: Forecasted global sales, by drug ($m), 2019-23
Back to Top